Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics

Psychopharmacology

Volumn 128, Issue 4, 1996, Pages 371-379

  Tarazi, Frank I ^a,b   Florijn, Wouter J ^a,c   Creese, Ian ^a  

^a RUTGERS UNIVERSITY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

autoradiography; caudate putamen; glutamate receptors; hippocampus; medial prefrontal cortex; schizophrenia; typical and atypical antipsychotics

Indexed keywords

6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; CLOZAPINE; DIZOCILPINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; GLUTAMATE RECEPTOR; HALOPERIDOL; IONOTROPIC RECEPTOR; KAINIC ACID; KAINIC ACID RECEPTOR; KAINIC ACID RECEPTOR AGONIST; KETANSERIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; RACLOPRIDE; RADIOISOTOPE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; DENTATE GYRUS; EXTRAPYRAMIDAL SYMPTOM; HIPPOCAMPUS; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ASSAY; RAT; RECEPTOR BINDING; REGULATORY MECHANISM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; HALOPERIDOL; MALE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; RECEPTORS, GLUTAMATE; SALICYLAMIDES; TIME FACTORS;

EID: 0029903447     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050147     Document Type: Article

References (58)

1. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12: 366 375
2. Beart PM, Lodge D (1990) Chronic administration of MK-801 and the NMDA receptor: further evidence for reduced sensitivity of the primary acceptor site from studies with the cortical wedge preparation. J Pharm Pharmacol 42: 354 355
3. Bolden C, Cusack B, Richelson E (1991) Clozapine is a selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 192:205 209
4. Bogerts B, Meertz E, Schonfeld-Bausch R (1985) Basal ganglia and limbic system pathology in schizophrenia. A morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 42: 784 791
5. Brown R, Colter N, Corsellis JAN, Crow TJ, Frith CD, Jagoe R, Johnstone FC, Marsh L (1986) Postmortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry 43: 36 42
6. Byrd JC, Bykov V, Rothman R (1987) Chronic haloperidol treatment up-regulates rat brain PCP receptors. Eur J Pharmacol 140: 121 122
7. Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1: 179 186
8. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75: 221 226
9. Carlsson M, Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia implications for schizophrenia and Parkinson's disease. Trends Neurosci 13: 272 276
10. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 3: 1687 1693
11. 2 receptor blocker, in acute schizophrenia: an open trial. Int Clin Psychopharmacol 4: 61 70
12. 1 and N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 259: 1064 1072
13. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474 1486
14. Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ (1989) Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52: 1781 1786
15. Deutsch SI, Mastrpaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989) A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacology with glycine. Clin Neuropharmacol 12: 1 13
16. Falkai P, Borgets B (1986) Cell loss in the hippocampus of schizophrenia. Eur Arch Psychiatr Neurol Sci 236: 154 161
17. 2-dopamine receptor occupancy by PET. Psychopharmacology 94:1 7
18. 3H]-glutamate binding in the rat hippocampal formation following fimbria-fornix lesions. Exp Neurol 115: 271 281
19. Greenamyre JT, Olson JMM, Penney JB, Young AB (1985) Autoradiographic characterization of N-methyl-D-aspartate, quisqualate- and kainate sensitive glutamate binding sites. J Pharmacol Exp Ther 233: 254 263
20. Halpain S, Girault JA, Greengard P (1990) Activation of NMDA receptors induce deophosphorylaton of DARPP-32 in rat striatal slices. Nature 343: 369 372
21. Honore T, Davies SN, Drejer J, Fleteher EJ, Jacobsen P (1988) Quinoxalinediones: potent competitive non-NMDA receptor antagonists. Science 241: 701 703
22. Javitt DC (1987) Negative symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9: 12 35
23. Javitt DC, Zukin SR (1991) Recent advances in the pheneyclidine model of schizophrenia. Am J Psychiatry 148: 1301 1308
24. Kakigi T, Gao X-M, Tamminga CA (1995) Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J Neural Transm 101: 41 49
25. Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptors expressed in xenopus oocytes. Science 241: 835 837
26. Kerwin R, Patel S, Meldrum B (1990) Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39: 25 32
27. 2 receptors in the rat brain. Biochem Pharmacol 34:2251 2255
28. 3H]Amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: minimal changes in postmortem brains of schizophrenics. J Neurochem 59:829 837
29. Lidsky TI, Yablonsky-Alter E, Zuck L, Banerjee SP (1993) Antiglutamatergic effects of clozapine. Neurosci Lett 163: 155 158
30. 3H]D-AP5 suggesting downregulation of the cortical N-methyl-D-aspartate receptors. Neuroseience 30:87 94
31. 2 receptors. Eur J Pharmacol 145:31 38
32. Mehta AK, Ticku MR (1990) Role of N-methyl-D-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Sci 46:37 42
33. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18 S27
34. Meshul CK, Janowsky A, Casey DE, Stallbaumer RK, Taylor B (1992) Effect of haloperidol and clozapine on the density of "perforated" synapses in caudate, nucleus accumbens and medial prefrontal cortex. Psychopharmacology 106: 45 52
35. 3H-kainic acid binding sites in the rat CNS as determined by autoradiography. Brain Res 252:91 100
36. Monaghan DT, Bridges RJ, Cotwan CW (1989) The excitatory amino acid receptors: their classes, pharmacology, and distinct properties in the function of the central nervous system. Ann Rev Pharmacol Toxicol 29:365 402
37. Nakanishi S (1992) Molecular diversity of glutamate receptors and implications for brain functions. Science 258:597 603
38. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 40:245 250
39. O'Dell SJ, La Hoste GJ, Widmark CB, Shapiro RM, Potkin SG, Marshall JF (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6: 146 153
40. Quirion R, Bayorh MA, Zerbe RL, Pert CB (1982) Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain. Pharmacol Biochem Behav 17:699 702
41. 3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine and polyamines. J Neurochem 51:830 836
42. 2 dopamine receptors and σ/haloperidol binding sites in rat brain. Mol Neuropharmacol 1:17 22
43. Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621 623
44. Simpson MDC, Slater P, Royston MC, Deakin JFW (1992) Alterations in phenylcyclidine and sigma binding sites in schizophrenic brains: effects of disease process and neuroleptic medication. Schizophr Res 6:41 48
45. Singh NA, Bush LG, Gibb JW, Hanson GR (1990) Dopamine-mediated changes in central nervous system neurotensin systems: a role for NMDA receptors. Eur J Pharmacol 187: 337 344
46. 3H]MK-801) in rat brain: regional effects of polyamines. J Pharmacol Exp Ther 256:811 819
47. Ulas J, Cotman CW (1993) Excitatory amino acid receptors in schizophrenia. Schizophr Bull 19:105-117
48. Ulas J, Nguyen L, Cotman CW (1993) Chronic haloperidol treatment enhances binding to NMDA receptors in rat cortex. Neuro Report 4:1049-1051
49. 3H-kainic acid binding sites in the rat forebrain. Eur J Pharmacol 86:361-371
50. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350:614 619
51. Wachtel H, Turski L (1990) Glutamate: a new target in schizophrenia. Trends Pharmacol Sci 11:219 220
52. White FJ, Wang RX (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057
53. 2) receptors in the rat brain. Brain Res 487: 288 298
54. Yamamoto BK, Cooperman MA (1994) Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 14:4159 4166
55. Yoshida Y, Ono T, Kizu A, Fukushima R, Miyagishi T (1991) Striatal N-methyl-D-aspartate receptors in haloperidol-induced catalepsy. Eur J Pharmacol 203:173-180
56. Yoshida Y, Ono T, Kawano K, Miyagishi T (1994) Distinct sites of dopaminergic and glutamatergic regulation of haloperidol-induced catalepsy within the rat caudate-putamen. Brain Res 639:139-148
57. Young AB, Fagg GE (1990) Excitatory amino acid receptors in the brain: membrane binding and receptor autoradiographic approaches. Trends Pharmacol Sci 11:126-133
58. 4 receptor agonist. Eur J Pharmacol [Mol Pharmacol] 269:R1 R2